Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Research and Development Grants

University of Toronto

$65,000.00

A synthetic biology platform for the discovery and commercialization of natural products.

FY 2019-20

Summary
Specialized metabolites (also known as natural products) are naturally-occurring molecules made by environmental microorganisms that have potent biological activities. Some are beneficial: penicillin, vancomycin, amphoteracin and tetracycline are used as antibiotics to fight bacterial and fungal infections. Conversely, some are harmful. An example is aflatoxin, a potentially fatal toxin produced by food-contaminating Aspergillus species and the causative agent of liver damage and cancer. This proposal concerns specialized metabolites that are of shared interest between the Nodwell laboratory and Toronto Research Chemicals: aflatoxin and pepticinnamin. The Nodwell laboratory is developing pepticinnamin as an anti fungal drug; Toronto Research Chemicals needs a source of aflatoxin to serve as a standard in portable detection kits for aflatoxin. The major limitation in this area of research and commercialization is that the specialized metabolites tend to be produced in very small amounts by the microbes that make them. The molecules themselves are usually too complicated to produce synthetically so this is a major road block. The purpose of this collaborative effort between the Nodwell lab and Toronto Research Chemicals is to overcome this road block by developing methods for producing these molecules at very high levels. To this end we will develop strategies for optimizing the biosynthetic genes for these molecules for higher level expression in living cells. We will engineer these optimized genes into ""chassis"" strains designed for controlled gene expression. Finally we will develop industrial-scale culture conditions for producing each molecule at a scale appropriate for our research and commercialization needs. This is an initial focus: we regard this work on aflatoxin and pepticinnamin as a trial effort in which we will generate a platform that we can apply to many other compounds of shared mutual interest in the years to come. Our hope is that this will lead to ongoing collaboration.
Program
Collaborative Research and Development Grants
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
537380-2018
Name nom
Nodwell, Justin
Department département
Biochemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2018
Award amount
65000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5408
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Metabolism
Research subject fr
Métabolisme
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
A synthetic biology platform for the discovery and commercialization of natural products.
Keyword
NSERC
Application summary
Specialized metabolites (also known as natural products) are naturally-occurring molecules made by environmental microorganisms that have potent biological activities. Some are beneficial: penicillin, vancomycin, amphoteracin and tetracycline are used as antibiotics to fight bacterial and fungal infections. Conversely, some are harmful. An example is aflatoxin, a potentially fatal toxin produced by food-contaminating Aspergillus species and the causative agent of liver damage and cancer. This proposal concerns specialized metabolites that are of shared interest between the Nodwell laboratory and Toronto Research Chemicals: aflatoxin and pepticinnamin. The Nodwell laboratory is developing pepticinnamin as an anti fungal drug; Toronto Research Chemicals needs a source of aflatoxin to serve as a standard in portable detection kits for aflatoxin. The major limitation in this area of research and commercialization is that the specialized metabolites tend to be produced in very small amounts by the microbes that make them. The molecules themselves are usually too complicated to produce synthetically so this is a major road block. The purpose of this collaborative effort between the Nodwell lab and Toronto Research Chemicals is to overcome this road block by developing methods for producing these molecules at very high levels. To this end we will develop strategies for optimizing the biosynthetic genes for these molecules for higher level expression in living cells. We will engineer these optimized genes into ""chassis"" strains designed for controlled gene expression. Finally we will develop industrial-scale culture conditions for producing each molecule at a scale appropriate for our research and commercialization needs. This is an initial focus: we regard this work on aflatoxin and pepticinnamin as a trial effort in which we will generate a platform that we can apply to many other compounds of shared mutual interest in the years to come. Our hope is that this will lead to ongoing collaboration.